Codexis (CDXS) Hits New 1-Year High at $8.18

Codexis, Inc. (NASDAQ:CDXS) hit a new 52-week high during trading on Tuesday . The company traded as high as $8.18 and last traded at $7.85, with a volume of 246400 shares trading hands. The stock had previously closed at $7.70.

Several research analysts recently issued reports on the stock. BidaskClub raised shares of Codexis from a “hold” rating to a “buy” rating in a report on Friday, December 15th. Jefferies Group reissued a “buy” rating and set a $9.00 price target (up from $8.00) on shares of Codexis in a report on Monday, October 2nd. HC Wainwright increased their price target on shares of Codexis from $8.00 to $8.50 and gave the stock a “buy” rating in a report on Friday, October 13th. Zacks Investment Research cut shares of Codexis from a “hold” rating to a “sell” rating in a report on Monday, September 4th. Finally, ValuEngine raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $7.50.

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN increased its holdings in Codexis by 103.2% in the second quarter. Wells Fargo & Company MN now owns 119,294 shares of the biotechnology company’s stock valued at $650,000 after buying an additional 60,600 shares in the last quarter. Telemark Asset Management LLC purchased a new position in Codexis in the third quarter valued at about $13,633,000. William Blair Investment Management LLC increased its holdings in Codexis by 10.5% in the second quarter. William Blair Investment Management LLC now owns 1,090,072 shares of the biotechnology company’s stock valued at $5,941,000 after buying an additional 103,233 shares in the last quarter. Baillie Gifford & Co. increased its holdings in Codexis by 1.1% in the third quarter. Baillie Gifford & Co. now owns 1,478,097 shares of the biotechnology company’s stock valued at $9,830,000 after buying an additional 16,684 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Codexis by 28.8% in the second quarter. Northern Trust Corp now owns 453,656 shares of the biotechnology company’s stock valued at $2,473,000 after buying an additional 101,432 shares in the last quarter. 65.71% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Codexis (CDXS) Hits New 1-Year High at $8.18” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/12/21/codexis-cdxs-hits-new-1-year-high-at-8-18.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit